← Research ProtocolsCagrilintide
STUDIED EXPOSURE MAP / 2021
Cagrilintide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / DOSE-FINDING PHASE 2THE LANCETSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
0.3 mg
SC · once weekly
0.6 mg
SC · once weekly
1.2 mg
SC · once weekly
2.4 mg
SC · once weekly
4.5 mg
SC · once weekly
Context: Five cagrilintide dose groups were studied over 26 weeks, alongside comparator arms. These are randomized trial exposures, not recommendations.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / THE LANCET
Once-weekly cagrilintide for weight management: dose-finding phase 2 trial
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2021
01 / DESIGNMulticenter · randomized · double-blind · placebo- and active-controlled · dose finding
02 / POPULATION / MODELAdults with overweight or obesity
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAME26 weeks
05 / PRIMARY QUESTIONDose-response relationship for body weight, safety and tolerability
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.